- Home
- IMNN vs GENK Comparison
IMNN vs GENK Comparison
Compare IMNN & GENK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMNN | GENK |
|---|---|---|
| Founded | 1982 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5M | 14.1M |
| IPO Year | 1985 | 2023 |
Fundamental Metrics
Financial Performance| Metric | IMNN | GENK |
|---|---|---|
| Price | $3.55 | $2.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $182.61 | $5.67 |
| AVG Volume (30 Days) | ★ 76.9K | 64.0K |
| Earning Date | 02-26-2026 | 03-05-2026 |
| Dividend Yield | N/A | ★ 1.30% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $217,449,000.00 |
| Revenue This Year | N/A | $8.46 |
| Revenue Next Year | N/A | $8.17 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 9.36 |
| 52 Week Low | $2.99 | $2.10 |
| 52 Week High | $41.22 | $7.41 |
Technical Indicators
Market Signals| Indicator | IMNN | GENK |
|---|---|---|
| Relative Strength Index (RSI) | 47.02 | 43.95 |
| Support Level | $3.39 | $2.31 |
| Resistance Level | $3.77 | $2.43 |
| Average True Range (ATR) | 0.24 | 0.14 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 29.27 | 5.66 |
Price Performance
Historical ComparisonAbout IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
About GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. It operates 43 Gen Korean BBQ restaurants in the United States.